BRIEF-Tempest Receives Orphan Drug Designation From U.S. FDA For Amezalpat

Reuters
06 Jan
BRIEF-Tempest Receives Orphan Drug Designation From U.S. FDA For Amezalpat

Jan 6 (Reuters) - Tempest Therapeutics Inc TPST.O:

  • TEMPEST RECEIVES ORPHAN DRUG DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR AMEZALPAT TO TREAT PATIENTS WITH HEPATOCELLULAR CARCINOMA $(HCC)$

Source text: nGNX9Dyhdg

Further company coverage: TPST.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10